Associated tags: Health, Patient, Oncology, Biotechnology, Medical imaging, Science, Research, Metastasis, Genetics, Melanoma, Recurrence, Sentinel lymph node, Other Health, CM, Pharmaceutical industry, Survival, GEP, SEER, Skin
Oncology,
Health,
Other Health,
General Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Sentinel lymph node,
SCC,
Congress,
Castle,
Risk,
Patient,
Neoplasm,
Research,
NCCN,
AJCC,
National Comprehensive Cancer Network,
Risk assessment,
Lymph node,
Carcinoma,
Melanoma,
Trial of the century,
Recurrence,
Metastasis,
SLN,
Medical imaging Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.
Key Points:
- Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.
- This study explored the cost-savings impact of using the DecisionDx-Melanoma test to guide risk-aligned clinical decision-making versus using the current melanoma staging standard, a patient’s AJCC stage.
- Summary: The DecisionDx-SCC test uses a patient’s tumor biology to independently predict risk of regional or distant metastasis in patients with high-risk SCC.
- These data demonstrate that DecisionDx-SCC improves the accuracy of risk assessment based solely on clinicopathological risk factors, leading to more appropriate risk-aligned management plans for patients with high-risk SCC.
Research,
Other Health,
General Health,
Oncology,
Medical Devices,
Genetics,
Health Technology,
Surgery,
Clinical Trials,
Science,
Biotechnology,
Health,
Other Science,
Online,
Sentinel lymph node,
Survival,
Risk,
Annual general meeting,
Patient,
Neoplasm,
Society,
Lymph,
Abstract,
SSO,
Lymph node,
Melanoma,
Trial of the century,
Recurrence,
Metastasis,
SLN,
Medical imaging “We have also demonstrated that our test is a strong and independent predictor of metastasis.
Key Points:
- “We have also demonstrated that our test is a strong and independent predictor of metastasis.
- The study that was orally presented at SSO 2024 demonstrates that patients who did avoid an SLNB procedure had excellent outcomes to date.
- Additionally, at three years, all patients with a low-risk DecisionDx-Melanoma test result were recurrence free (recurrence free survival of 100%).
- These data demonstrate that use of DecisionDx-Melanoma test results can guide accurate, risk-aligned clinical decision-making regarding the SLNB surgical procedure, within current guidelines.
Retrieved on:
Monday, February 26, 2024
Oncology,
Health,
Genetics,
Clinical Trials,
Research,
Science,
Biotechnology,
Recurrence,
RFS,
Hospital,
Metastasis,
IB,
MSS,
Risk,
Prognosis,
Death,
Patient,
Survival,
Disease,
Mortality,
Melanoma,
Medical imaging Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).
Key Points:
- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).
- Stage I CM tumors are considered low risk; however, since stage I encompasses a large group of patients diagnosed, many melanoma-specific deaths are seen in patients initially diagnosed with stage I disease.
- Thus, there is a clinical gap in the low-risk treatment pathway for stage I patients.
- The new study in Cancers provides further information that DecisionDx-Melanoma testing could enable more precise risk stratification in stage I melanomas than provided by traditional staging to better inform risk-appropriate clinical management.
Science,
Biotechnology,
Research,
Oncology,
General Health,
Health,
Genetics,
Clinical Trials,
Patient,
Castle,
Neoplasm,
Melanoma,
Skin,
Risk assessment,
SCC,
Risk,
Recurrence,
Immunotherapy,
Metastasis,
MF,
Gene expression,
Mycosis fungoides,
Psoriasis,
GEP,
Conference,
Atopic dermatitis,
PSO,
Coral,
Diagnosis,
Physician,
Medical imaging Posters will be displayed for viewing in the Coral Ballroom 2 through Jan. 16 at 1 p.m. Hawaii Standard Time.
Key Points:
- Posters will be displayed for viewing in the Coral Ballroom 2 through Jan. 16 at 1 p.m. Hawaii Standard Time.
- The i31-GEP ROR provides a more personalized, precise risk of tumor recurrence to guide clinical management of CM.
- Summary: This study evaluated the ability of DecisionDx-SCC to independently improve the identification of lower-staged tumors at increased risk of metastasis.
- Within a cohort of SCC patients considered lower risk by current staging alone, DecisionDx-SCC identified those at a substantially higher risk of metastasis.
Research,
Nursing,
Hospitals,
Biotechnology,
Managed Care,
Health,
Other Science,
Science,
Oncology,
NPS,
MMS,
Risk,
Patient,
Journal,
Melanoma,
Cancer,
Recurrence,
Neoplasm,
Metastasis,
Medical imaging,
Vaccine The study found that more than 90% of the NPs/PAs who completed a survey about DecisionDx-Melanoma believe that prognostic (i.e., risk-stratification) information about a patient’s melanoma is valuable and improves patient care.
Key Points:
- The study found that more than 90% of the NPs/PAs who completed a survey about DecisionDx-Melanoma believe that prognostic (i.e., risk-stratification) information about a patient’s melanoma is valuable and improves patient care.
- Of the 369 NPs/PAs who completed the survey, 176 (47.7%) reported using the DecisionDx-Melanoma test in the prior 12 months.
- 90.5% of the respondents felt that comprehensive prognostic testing, such as with DecisionDx-Melanoma, improves patient care.
- Most (62.1%) reported that a high-risk DecisionDx-Melanoma test result would alter their treatment plan for a patient with a thin tumor (≤1mm).
Retrieved on:
Tuesday, November 14, 2023
Mental Health,
Medical Supplies,
Genetics,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Oncology,
Research,
Annual general meeting,
NCCN,
ART,
Lymph node,
National Comprehensive Cancer Network,
Risk,
ASDS,
Patient,
BWH,
SLN,
SCC,
Abstract,
MPH,
Diagnosis,
University,
Medicare,
Society,
Summary,
GEP,
Metastasis,
T2A,
Pharmaceutical industry,
Medical imaging,
Brigham Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.
Key Points:
- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.
- “The robust data presented at ASDS underscores the value of GEP testing across multiple skin cancer indications” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.
- Summary: ART is recommended based on high-risk clinicopathologic features of SCC, but these criteria are wide-ranging, encompassing a broad range of patients.
- Additionally, a DecisionDx-SCC Class 2B result was the only risk factor that successfully identified patients who would benefit from ART.
Retrieved on:
Wednesday, October 18, 2023
Research,
Other Health,
General Health,
Oncology,
Medical Devices,
Hospitals,
Genetics,
Clinical Trials,
Science,
Biotechnology,
Stem Cells,
Health,
Other Science,
Lymph node,
Psoriasis,
GEP,
Atopic dermatitis,
Gene expression,
Patient,
Skin,
Pharmaceutical industry,
Paint,
Vaccine Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference® (FC23), taking place Oct. 19-22, 2023, in Las Vegas.
Key Points:
- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference® (FC23), taking place Oct. 19-22, 2023, in Las Vegas.
- “The breadth of data we are sharing at Fall Clinical reinforces our commitment to improving the care of patients with skin cancers and inflammatory skin conditions through innovative tests that can guide more informed disease management decisions,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
- Details regarding Castle’s posters at FC23 are included below.
- Posters will be available for viewing for the duration of the conference.
Retrieved on:
Thursday, October 5, 2023
Managed Care,
Research,
Other Health,
General Health,
Radiology,
Oncology,
Medical Devices,
Genetics,
Clinical Trials,
Science,
Biotechnology,
Health,
Other Science,
Algorithm,
American Joint Committee on Cancer,
Memorial Sloan Kettering Cancer Center,
Risk,
Recurrence,
MSKCC,
Lymph node,
Melanoma,
Anticancer Research,
Patient,
National Comprehensive Cancer Network,
SLN,
Sentinel lymph node,
Metastasis,
CM,
NCCN,
Medical imaging Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).
Key Points:
- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).
- The MSKCC nomogram, which uses logistic regression and only clinical and pathologic factors to predict a patient’s SLN positivity risk.
- Patients from previously published multicenter cohorts with T1-T2 tumors who had undergone the SLNB procedure (n=465) were analyzed using both DecisionDx-Melanoma and the MSKCC nomogram.
- DecisionDx-Melanoma also demonstrated better accuracy in predicting SLN positivity, including higher sensitivity (95% vs. 81%) and negative predictive value (97% vs. 90%) than the MSKCC nomogram.
Retrieved on:
Monday, September 25, 2023
Oncology,
Health,
Other Health,
Managed Care,
Research,
Science,
Biotechnology,
Rigel,
Melanoma,
Incidence,
Dermatology,
ETF,
Patient,
Sentinel lymph node,
Metastasis,
Biology,
ABCD syndrome,
Neoplasm,
Recurrence,
Skin,
Caregiver,
Disease,
Medical imaging,
Medicine “Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member. “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care. At the end of the day, we are all working together to make an impact in people’s lives and perhaps provide something even more powerful than that … hope for the future.”
Key Points:
- “Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member.
- “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care.
- IMPACT Melanoma is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives.
- The live broadcast will begin at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York.
Research,
Genetics,
Biotechnology,
Other Health,
Health,
General Health,
Other Science,
Science,
Oncology,
SCC,
Cone Health Women's Hospital,
GEP,
Cancer,
Head,
American Head,
American Joint Committee on Cancer,
CM,
Patient,
BWH,
Hospital,
Conference,
Metastasis,
Pharmaceutical industry,
Medical imaging,
QC,
Brigham Key Points:
- Details are as follows:
“Traditional staging methods rely on a limited set of clinicopathologic risk factors to categorize cancer patients into different stages,” said Newman.
- “While these factors provide important information, they may not fully capture the underlying biological heterogeneity and variability in tumor behavior.
- Additionally, the metastatic risk predictions provided by AJCC8 and BWH staging were significantly improved when DecisionDx-SCC test results were included.
- Overall, the data demonstrated that combining the test’s results with AJCC8 staging significantly improved risk prediction over use of either alone, providing actionable information that can enable risk-aligned patient care.
